Which has stronger earnings & valuation, DSGN or IPHA?

Innate Pharma has higher revenue and earnings than Design Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Innate Pharma $10.19M 16.22 -$55.64M N/A N/A

Is DSGN or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Innate Pharma N/A N/A N/A

Which has higher earnings and valuation, ANRO or IPHA?

Innate Pharma has higher revenue and earnings than Alto Neuroscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Innate Pharma $10.19M 16.22 -$55.64M N/A N/A

Is ANRO or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Innate Pharma N/A N/A N/A

Which has stronger earnings and valuation, ALLO or IPHA?

Innate Pharma has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 32,789.25 -$190.89M -$0.77 N/A Innate Pharma $10.19M 16.22 -$55.64M N/A N/A

Is ALLO or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Innate Pharma N/A N/A N/A

Which has higher earnings and valuation, IPHA or DRUG?

Bright Minds Biosciences has lower revenue, but higher earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.22 -$55.64M N/A N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A

Is IPHA or DRUG more profitable?

Innate Pharma's return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Bright Minds Biosciences N/A -20.58% -20.25%

Which has preferable valuation and earnings, SLDB or IPHA?

Innate Pharma has higher revenue and earnings than Solid Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Innate Pharma $10.19M 16.22 -$55.64M N/A N/A

Is SLDB or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Innate Pharma N/A N/A N/A

Innate Pharma (IPHA) Competitors

$1.76 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.72 -0.04 (-2.56%)

As of 06/12/2026 07:58 PM Eastern

Compare

IPHA vs. DSGN, ANRO, ALLO, DRUG, and SLDB

Should you buy Innate Pharma stock or one of its competitors? MarketBeat compares Innate Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innate Pharma include Design Therapeutics (DSGN), Alto Neuroscience (ANRO), Allogene Therapeutics (ALLO), Bright Minds Biosciences (DRUG), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does Innate Pharma compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Innate Pharma has higher revenue and earnings than Design Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Innate Pharma	$10.19M	16.22	-$55.64M	N/A	N/A

In the previous week, Design Therapeutics had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.89 beat Design Therapeutics' score of 0.94 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Design Therapeutics	Positive
Innate Pharma	Very Positive

Innate Pharma's return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Innate Pharma	N/A	N/A	N/A

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Design Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 50.41%. Innate Pharma has a consensus price target of $5.00, indicating a potential upside of 184.09%. Given Innate Pharma's higher possible upside, analysts clearly believe Innate Pharma is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Innate Pharma beats Design Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Alto Neuroscience presently has a consensus price target of $35.25, indicating a potential upside of 63.46%. Innate Pharma has a consensus price target of $5.00, indicating a potential upside of 184.09%. Given Innate Pharma's higher possible upside, analysts clearly believe Innate Pharma is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Innate Pharma has higher revenue and earnings than Alto Neuroscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Innate Pharma	$10.19M	16.22	-$55.64M	N/A	N/A

Alto Neuroscience has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

0.2% of Innate Pharma shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Alto Neuroscience and Alto Neuroscience both had 1 articles in the media. Innate Pharma's average media sentiment score of 1.89 beat Alto Neuroscience's score of 0.00 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Innate Pharma	Very Positive

Innate Pharma's return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Innate Pharma	N/A	N/A	N/A

Summary

Innate Pharma beats Alto Neuroscience on 9 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Innate Pharma has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	32,789.25	-$190.89M	-$0.77	N/A
Innate Pharma	$10.19M	16.22	-$55.64M	N/A	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 1 articles in the media. Innate Pharma's average media sentiment score of 1.89 beat Allogene Therapeutics' score of 0.69 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Positive
Innate Pharma	Very Positive

Innate Pharma's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Innate Pharma	N/A	N/A	N/A

Allogene Therapeutics currently has a consensus price target of $8.52, suggesting a potential upside of 348.54%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 184.09%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Allogene Therapeutics and Innate Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Bright Minds Biosciences?

Innate Pharma (NASDAQ:IPHA) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Bright Minds Biosciences has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.22	-$55.64M	N/A	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Innate Pharma has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.53, suggesting that its share price is 653% less volatile than the broader market.

In the previous week, Innate Pharma and Innate Pharma both had 1 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.92 beat Innate Pharma's score of 1.89 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Innate Pharma	Very Positive
Bright Minds Biosciences	Very Positive

Innate Pharma presently has a consensus target price of $5.00, indicating a potential upside of 184.09%. Bright Minds Biosciences has a consensus target price of $143.83, indicating a potential upside of 135.99%. Given Innate Pharma's higher possible upside, research analysts clearly believe Innate Pharma is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Innate Pharma's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-20.58%	-20.25%

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Innate Pharma and Bright Minds Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Innate Pharma has higher revenue and earnings than Solid Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Innate Pharma	$10.19M	16.22	-$55.64M	N/A	N/A

Solid Biosciences currently has a consensus target price of $17.00, indicating a potential upside of 138.10%. Innate Pharma has a consensus target price of $5.00, indicating a potential upside of 184.09%. Given Innate Pharma's higher probable upside, analysts clearly believe Innate Pharma is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Innate Pharma's return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Innate Pharma	N/A	N/A	N/A

Solid Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, Solid Biosciences had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.89 beat Solid Biosciences' score of 1.09 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Solid Biosciences	Positive
Innate Pharma	Very Positive

Summary

Innate Pharma beats Solid Biosciences on 7 of the 12 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$165.30M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.00	24.00	24.42
Price / Sales	16.22	304.30	514.65	112.54
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-6.77	8.32	10.69	6.82
Net Income	-$55.64M	$23.94M	$3.57B	$337.56M
7 Day Performance	N/A	1.84%	0.61%	1.16%
1 Month Performance	-12.87%	-0.04%	1.56%	3.16%
1 Year Performance	-7.12%	44.82%	25.44%	30.60%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	3.2999 of 5 stars	$1.76 flat	$5.00 +184.1%	-7.1%	$165.30M	$10.19M	N/A	220	High Trading Volume
DSGN Design Therapeutics	2.7943 of 5 stars	$10.55 +0.9%	$16.50 +56.4%	+185.7%	$653.30M	N/A	N/A	40	Gap Down
ANRO Alto Neuroscience	1.8638 of 5 stars	$21.15 +15.9%	$35.25 +66.7%	+793.0%	$640.11M	N/A	N/A	N/A	News Coverage
ALLO Allogene Therapeutics	2.9529 of 5 stars	$1.82 -1.6%	$8.52 +368.3%	+41.8%	$638.54M	$20K	N/A	310
DRUG Bright Minds Biosciences	3.4143 of 5 stars	$67.80 +3.9%	$143.83 +112.1%	+121.0%	$635.32M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. DSGN, ANRO, ALLO, DRUG, and SLDB

How does Innate Pharma compare to Design Therapeutics?

Summary

How does Innate Pharma compare to Alto Neuroscience?

Summary

How does Innate Pharma compare to Allogene Therapeutics?

Summary

How does Innate Pharma compare to Bright Minds Biosciences?

Summary

How does Innate Pharma compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. DSGN, ANRO, ALLO, DRUG, and SLDB

How does Innate Pharma compare to Design Therapeutics?

Which has more risk & volatility, DSGN or IPHA?

Which has stronger earnings & valuation, DSGN or IPHA?

Does the media prefer DSGN or IPHA?

Is DSGN or IPHA more profitable?

Do institutionals & insiders have more ownership in DSGN or IPHA?

Do analysts recommend DSGN or IPHA?

Summary

How does Innate Pharma compare to Alto Neuroscience?

Do analysts recommend ANRO or IPHA?

Which has higher earnings and valuation, ANRO or IPHA?

Which has more volatility and risk, ANRO or IPHA?

Do insiders and institutionals have more ownership in ANRO or IPHA?

Does the media favor ANRO or IPHA?

Is ANRO or IPHA more profitable?

Summary

How does Innate Pharma compare to Allogene Therapeutics?

Which has more volatility & risk, ALLO or IPHA?

Which has stronger earnings and valuation, ALLO or IPHA?

Do insiders & institutionals hold more shares of ALLO or IPHA?

Does the media favor ALLO or IPHA?

Is ALLO or IPHA more profitable?

Do analysts prefer ALLO or IPHA?

Summary

How does Innate Pharma compare to Bright Minds Biosciences?

Which has higher earnings and valuation, IPHA or DRUG?

Which has more volatility and risk, IPHA or DRUG?

Does the media favor IPHA or DRUG?

Do analysts prefer IPHA or DRUG?

Is IPHA or DRUG more profitable?

Do institutionals & insiders have more ownership in IPHA or DRUG?

Summary

How does Innate Pharma compare to Solid Biosciences?

Do insiders and institutionals have more ownership in SLDB or IPHA?

Which has preferable valuation and earnings, SLDB or IPHA?

Do analysts rate SLDB or IPHA?

Is SLDB or IPHA more profitable?

Which has more risk and volatility, SLDB or IPHA?

Does the media prefer SLDB or IPHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools